Plasma somatostatin levels in patients with chronic idiopathic intestinal pseudo-obstruction

M. Peracchi, G. Basilisco, B. Bareggi, M. Quatrini, P. Velio, Paolo A. Bianchi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Somatostatin participates in the control of gut motility. Recently, somatostatin analogs have been proposed as therapeutic agents for chronic intestinal pseudo-obstruction, although the endogenous somatostatin pattern has never been assessed in this syndrome. We aimed to evaluate fasting and postprandial plasma somatostatin levels in patients with chronic idiopathic intestinal pseudo-obstruction (CIIP). Methods: We studied eight patients with CIIP and 10 healthy volunteers. Blood samples were taken at regular intervals while patients and subjects fasted and during the 3 h after a standard solid/liquid meal (550 kcal) had been eaten. Somatostatin was measured by radioimmunoassay. Results: Fasting somatostatin levels were normal, whereas postprandial peptide responses were markedly impaired or even absent in patients with CIIP. Conclusions: An impaired postprandial somatostatin response in patients with ClIP seems to be characteristic of this heterogenous disorder. Whether the lack of somatostatin response to a meal identifies patients with severe gut dysmotility for whom treatment with somatostatin analogs would be useful remains to be verified.

Original languageEnglish
Pages (from-to)1884-1886
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume92
Issue number10
Publication statusPublished - Oct 1997

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Plasma somatostatin levels in patients with chronic idiopathic intestinal pseudo-obstruction'. Together they form a unique fingerprint.

Cite this